Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma

被引:1
|
作者
Todoroki, Keita [1 ,2 ]
Abe, Yushi [1 ,2 ]
Matsuo, Katsuhisa [1 ,2 ]
Nomura, Hidetoshi [1 ]
Kawahara, Akihiko [3 ]
Nakamura, Yoshiaki [4 ]
Nakamura, Moriyoshi [1 ]
Seki, Naoko [1 ]
Kusukawa, Jingo [1 ]
机构
[1] Kurume Univ, Dent & Oral Med Ctr, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan
[2] Kouhoukai Med Corp, Takagi Hosp, Dept Dent & Oral Surg, Okawa, Fukuoka 8310016, Japan
[3] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka 8300011, Japan
[4] Oita Saiseikai Hita Hosp, Dept Dent & Oral Surg, Hita, Oita 8771292, Japan
关键词
CSC; OSCC; CD44v3; CD24; programmed cell death ligand 1; programmed cell death 1; immune checkpoint inhibitors; HEAD; PD-L1; CD24; IDENTIFICATION; IMMUNOTHERAPY; POPULATION; RECURRENT;
D O I
10.3892/ol.2024.14213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between cancer stem cells (CSCs) in oral squamous cell carcinoma (OSCC) and programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) remains unclear. Therefore, the present study aimed to clarify the association between the CD44v3(high)/CD24(low) immunophenotype of CSCs in OSCC and PD-L1/PD-1 co-expression, and to assess the prognostic effect of CSCs in terms of immune checkpoint molecules. Formalin-fixed, paraffin-embedded tissue samples and clinicopathological data from 168 patients with OSCC were retrospectively retrieved. Immunohistochemical staining and reverse transcription quantitative polymerase chain reaction were applied to a tissue microarray of the invasive front of each case. Semi-automated cell counting was used to assess CD44v3, CD24, PD-L1 and PD-1 expression by immunohistochemistry (IHC) using a digital image analysis program. Associations between immunological markers and clinicopathological variables were estimated. Patients with the CSC immunophenotype CD44v3(high)/CD24(low), and patients with a high PD-L1/PD-1-positive cell density in the tumor parenchyma and stroma had significantly lower survival rates. Furthermore, patients with the CSC immunophenotype (CD44v3(high)/CD24(low)) and high PD-L1/PD-1 co-expression had even lower survival rates (P<0.01, log-rank test). Notably, there was a positive correlation between CD44v3 and PD-L1 expression (tau=0.1096, P=0.0366, Kendall rank correlation coefficient) and a negative correlation between CD24 and PD-1 expression (tau=-0.1387, P=0.0089, Kendall rank correlation coefficient). Additionally, the high CD44v3 expression group, as determined by IHC, exhibited significantly decreased expression of U2 small nuclear RNA auxiliary factor 1 (U2AF1) at the mRNA level compared with that in the low CD44v3 expression group (P<0.001, Mann-Whitney U test), and U2AF1 and PD-L1 mRNA expression exhibited a significant negative correlation (tau=-0.3948, P<0.001, Kendall rank correlation coefficient). In conclusion, CSCs in OSCC may evade host immune mechanisms and maintain CSC stemness via PD-L1/PD-1 co-expression, resulting in unfavorable clinical outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type
    Jae-Cheol Jo
    Misung Kim
    Yunsuk Choi
    Hyun-Jung Kim
    Ji Eun Kim
    Seoung Wan Chae
    Hawk Kim
    Hee Jeong Cha
    Annals of Hematology, 2017, 96 : 25 - 31
  • [42] Evaluation of Programmed Death Ligand 1 Immunohistochemistry in Cytology Specimens of Head and Neck Squamous Cell Carcinoma
    Heidarian, Amin
    Wenig, Bruce M.
    Hernandez-Prera, Juan C.
    CANCER CYTOPATHOLOGY, 2022, 130 (02) : 91 - 95
  • [43] Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma
    Richter, Igor
    Jirasek, Tomas
    Cermakova, Eva
    Bartos, Jiri
    Buchler, Tomas
    Dvorak, Josef
    JOURNAL OF BUON, 2019, 24 (05): : 2155 - 2160
  • [44] Determining programmed cell death ligand 1 expression in circulating tumor cells of patients with clear cell renal cell carcinoma and its correlation with response to programmed cell death protein 1 inhibitors
    Chen, Bo-Han
    Kao, Chien-Chang
    Xu, Ting
    Yang, Yung-Ning
    Cha, Tai-Lung
    Tsai, Yi-Ta
    Liu, Shu-Yu
    Wu, Sheng-Tang
    Meng, En
    Tsao, Chih-Wei
    Chen, Chin-Li
    Sun, Guang-Huan
    Yu, Dah-Shyong
    Chang, Sun-Yran
    Yang, Ming-Hsin
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (09) : 947 - 954
  • [45] The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma
    Xiao, Wen-jun
    Xu, Fu-jiang
    Zhang, Xuan
    Zhou, Shu-xian
    Zhang, Hai-liang
    Dai, Bo
    Zhu, Yao
    Shi, Guo-hai
    Shen, Yi-jun
    Zhu, Yi-ping
    Qu, Yuan-yuan
    Zhao, Jian-Yuan
    Ye, Ding-wei
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [46] Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix
    Liu, Rongyu
    He, Xinlin
    Li, Zhengyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [47] PROGRAMMED CELL DEATH PROTEIN 1 AND PROGRAMMED DEATH LIGAND 1 EXPRESSION IN NEUROENDOCRINE CARCINOMAS OF THE URINARY BLADDER
    Acikalin, Arbil
    Bagir, Emine
    Inceman, Merve
    Deger, Mutlu
    Erdogan, Seyda
    POLISH JOURNAL OF PATHOLOGY, 2020, 71 (04) : 307 - 313
  • [48] The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma
    Schaper, K.
    Koether, B.
    Hesse, K.
    Satzger, I.
    Gutzmer, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (05) : 1354 - 1356
  • [49] Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes
    Matias Gompertz-Mattar
    Juan Perales
    Aditi Sahu
    Sebastián Mondaca
    Sergio Gonzalez
    Pablo Uribe
    Cristian Navarrete-Dechent
    Archives of Dermatological Research, 2022, 314 : 777 - 786
  • [50] PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER
    Zhang, Guo-Qiang
    Wei, Wei-Jun
    Song, Hong-Jun
    Sun, Zhen-Kui
    Shen, Chen-Tian
    Zhang, Xin-Yun
    Chen, Xiao-Yue
    Qiu, Zhong-Ling
    Luo, Quan-Yong
    ENDOCRINE PRACTICE, 2019, 25 (03) : 279 - 286